Capelan M - Search Results

1

Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.

Rafii S, Roda D, Geuna E, Jimenez B, Rihawi K, Capelan M, Yap TA, Molife LR, Kaye SB, de Bono JS, Banerji U. Rafii S, et al. Among authors: capelan m. Clin Cancer Res. 2015 Apr 15;21(8):1869-76. doi: 10.1158/1078-0432.CCR-14-2424. Epub 2015 Feb 3. Clin Cancer Res. 2015. PMID: 25649020 Free PMC article.

2

Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials.

Geuna E, Roda D, Rafii S, Jimenez B, Capelan M, Rihawi K, Montemurro F, Yap TA, Kaye SB, De Bono JS, Molife LR, Banerji U. Geuna E, et al. Among authors: capelan m. Br J Cancer. 2015 Dec 1;113(11):1541-7. doi: 10.1038/bjc.2015.373. Epub 2015 Nov 10. Br J Cancer. 2015. PMID: 26554652 Free PMC article.

3

Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.

Papadatos-Pastos D, Roda D, De Miguel Luken MJ, Petruckevitch A, Jalil A, Capelan M, Michalarea V, Lima J, Diamantis N, Bhosle J, Molife LR, Banerji U, de Bono JS, Popat S, O'Brien MER, Yap TA. Papadatos-Pastos D, et al. Among authors: capelan m. Eur J Cancer. 2017 Apr;75:56-62. doi: 10.1016/j.ejca.2016.12.026. Epub 2017 Feb 17. Eur J Cancer. 2017. PMID: 28214659

4

Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?

Capelan M, Roda D, Geuna E, Rihawi K, Bodla S, Kaye SB, Bhosle J, Banerji U, O'Brien M, de Bono JS, Popat S, Yap TA. Capelan M, et al. Lung Cancer. 2017 Sep;111:6-11. doi: 10.1016/j.lungcan.2017.06.005. Epub 2017 Jun 15. Lung Cancer. 2017. PMID: 28838399 Free article. Clinical Trial.

5

Febrile Neutropenia Rates According to Body Mass Index and Dose Capping in Women Receiving Chemotherapy for Early Breast Cancer.

Lote H, Sharp A, Redana S, Papadimitraki E, Capelan M, Ring A. Lote H, et al. Among authors: capelan m. Clin Oncol (R Coll Radiol). 2016 Sep;28(9):597-603. doi: 10.1016/j.clon.2016.02.003. Epub 2016 Feb 28. Clin Oncol (R Coll Radiol). 2016. PMID: 26936608

6

The prevalence of unmet needs in 625 women living beyond a diagnosis of early breast cancer.

Capelan M, Battisti NML, McLoughlin A, Maidens V, Snuggs N, Slyk P, Peckitt C, Ring A. Capelan M, et al. Br J Cancer. 2017 Oct 10;117(8):1113-1120. doi: 10.1038/bjc.2017.283. Epub 2017 Aug 31. Br J Cancer. 2017. PMID: 28859057 Free PMC article.

7

Rates of major complications during neoadjuvant and adjuvant chemotherapy for early breast cancer: An off study population.

Redana S, Sharp A, Lote H, Mohammed K, Papadimitraki E, Capelan M, Ring A. Redana S, et al. Among authors: capelan m. Breast. 2016 Dec;30:13-18. doi: 10.1016/j.breast.2016.07.019. Epub 2016 Aug 29. Breast. 2016. PMID: 27569021

8

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER⁺ breast cancer.

Palafox M, Monserrat L, Bellet M, Villacampa G, Gonzalez-Perez A, Oliveira M, Brasó-Maristany F, Ibrahimi N, Kannan S, Mina L, Herrera-Abreu MT, Òdena A, Sánchez-Guixé M, Capelán M, Azaro A, Bruna A, Rodríguez O, Guzmán M, Grueso J, Viaplana C, Hernández J, Su F, Lin K, Clarke RB, Caldas C, Arribas J, Michiels S, García-Sanz A, Turner NC, Prat A, Nuciforo P, Dienstmann R, Verma CS, Lopez-Bigas N, Scaltriti M, Arnedos M, Saura C, Serra V. Palafox M, et al. Among authors: capelan m. Nat Commun. 2022 Sep 7;13(1):5258. doi: 10.1038/s41467-022-32828-6. Nat Commun. 2022. PMID: 36071033 Free PMC article.

9

Impact of erythropoietin on the reduction of blood transfusions and on survival of lung cancer patients receiving first-line chemotherapy.

Fonseca PJ, Esteban E, de Vicente P, Luque M, Llorente B, Capelán M, Berros JP, Crespo G, Lacave AJ. Fonseca PJ, et al. Among authors: capelan m. Clin Transl Oncol. 2008 Jul;10(7):426-32. doi: 10.1007/s12094-008-0226-5. Clin Transl Oncol. 2008. PMID: 18628072

10

Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study.

Esteban E, Villanueva N, Muñiz I, Fernández Y, Fra J, Luque M, Jiménez P, Llorente B, Capelan M, Vieitez JM, Estrada E, Buesa JM, Jiménez-Lacave A. Esteban E, et al. Among authors: capelan m. Invest New Drugs. 2008 Feb;26(1):67-74. doi: 10.1007/s10637-007-9073-4. Epub 2007 Sep 5. Invest New Drugs. 2008. PMID: 17805486 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters